Capital Seeking: $41,000,000 US Pre-Money Valuation: $7,800,000 US

Company Summary

We aim to build a leading corporate enterprise through the acquisition of (4)

four companies that are life science leaders whose innovation influence
markets and shape the future of health. The company generates revenue
through proposed operating subsidiaries whose markets include: (4) four-
drug markets, neurodiagnostics, physiotherapy equipment for the combined
market size of $213,419,900,000

Executive Summary

Customer Problem

Advancements in medicine are hindered by pharmaceutical interests which

limits medicine to a microscopic view of disease rather than understanding
the macrocosm of health. We offer solutions to the current paradigm of
medicine through subsidiaries that are medical science leaders and advance
medicine with novel treatments for disease and biotech that advances the
understanding of disease.

Management Team

ERIKA ROBLES JONES, FOUNDER & PRESIDENT

ERIKA is an entrepreneur, medical scientist and artist. She completed her

graduate studies in Homeopathic Medicine and Medical Sciences at Ontario
College of Homeopathic Medicine in Canada. She completed her thesis on
the hermetic effect in homeopathy where she studied the toxicological
phenomenon that supports to support the mechanism within homeopathy.
She is Phd Candidate at University of Toronto through her research on the
biological complexities of the endocannabinoid system focusing on the role it
plays in maintaining health, in the pathological process, and its role in
developing medicine derived from cannabis through in-vivo and in-vitro
research. She spends her spare time in the arts, writing poetry or being
creative through a number of different mediums.
AZMATALI MEHRALI, CHIEF FINANCIAL OFFICER

Since 2006, Mr. Mehrali served as President of a private CFO consulting

business that provides regulatory and finance services to start-up brokerage
firms in Canada. With over 30 years of financial services experience, he has
also been CFO for several firms including Wells Fargo Canada Securities,
Brookfield Securities and Virtual Brokers. He also served as Vice President,
Finance, at Genuity Capital Markets; Assistant Controller, Investment
Technology Group Canada; Director of Finance, CIBC World Markets.
Recently, he has provided consulting services to start up medicinal cannabis
firms, assisting them as they proceed with public listing.

DR. JEFFREY PETERSON, CHIEF MEDICAL SCIENCE OFFICER

Dr. Jeffrey D. Peterson has a PhD in Immunology and Neuroscience and

started his career spending years researching a variety of autoimmune
diseases, including multiple sclerosis and Type I diabetes. He subsequently
worked for ten years in the Pharmaceutical and Biotech
industry as a Pharmacology researcher and Director, working to discover
novel drugs, therapies, and biomarkers at companies such as Boehringer
Ingelheim, Curagen Corporation, Abbott Bioresearch Center, and
PerkinElmer Inc. In this time, he developed further expertise in a range of
additional research areas, including oncology, cardiovascular disease, acute
and chronic inflammation, arthritis, pharmacokinetics, biodistribution, safety
pharmacology, and biomarker development. He has worked for the past 11
years in developing novel strategies for noninvasive assessment of disease
biology.

FODE TOURE, CHIEF TECHNOLOGY OFFICER

Mr. Touré obtained a PhD doctorate in computer science from University of
Montreal. With over ten years of experience in the Information Technology
field, Mr. Touré has served as Architect,Technology Director, and CTO in
several tech start-ups and companies. He is the architect & Tech Lead
behind an innovative blockchain-based advertising ecosystem and the
subject-matter expert (SME) for a blockchain-based multi-asset margin
trading crypto exchange. He has substantial expertise in real-time &
collaborative platforms, cloud (AWS,Azure), AdTech, Blockchain, ML, AI, IoT,
EdTech. His scientific experiences and publications have earned him
numerous awards and scholarships in more than one continent. Mr. Touré
is a Certified
Blockchain Solution Architect by Blockchain Training Alliance and
completed the Blockchain Technologies: Business Innovation and
Application program from the MIT Sloan School of Management.

AZZA ABDALLAH, CHIEF LEGAL OFFICER

The expertise and specialty of Azza is regarding securities law. After

receiving her LLB/JD in law from York University and her LLB from
University of London & Council of Legal Education, she continued her
education at the Canadian Securities Institute. Her stellar work experience
brings a wealth of knowledge in corporate finance. She recently acted as
Senior Vice President and Chief Compliance Officer for both KPMG
Corporate Finance Inc and KPMG for which she also acted as General
Counsel. Recently, she has made the decision to work only part-time for
KPMG due to family obligations. Before working at KPMG, she acted as
Senior Vice President, Director, General Counsel and Chief Compliance
Officer for many global financial corporations which include: Global Maxfin
Capital Corporation (IIROC Member) Global Maxfin Investment Corporation
(MFDA), Global Growth Assets Inc. (OSC - Investment Fund Manager), &
Global RESP Corporation

Product/Services

1. (4) Four Regulated Drugs derived from cannabis for cancer treatment,
neurodegenerative illness, epilepsy and pain management with proven efficacy in
medical science

2. Detection of neurological & psychiatric illness through a portable EEG device &
translation of brainwaves enabling in-office EEG recording and detection of
neurological and psychiatric illness, without requiring a neurologist or psychiatrist to
intervene for testing

3. Increasing neuronal plasticity by integrating A.I. and machine learning to analyze

and control body movement
Target Market:

1. Cancer Drug Market

2. Neurodegenerative Diseases Drug Market
3. Anti-Epileptic Drug Market
4. Neurodiagnostics Market
5. Physiotherapy Equipment Market

Business Model

Manufacturing & sale of novel medical treatment, novel neurodiagnostic devices,

and new medical technology are key activities. Each subsidiary offers propriety
scientific discovery by worldwide leaders in their field of research whose innovation
is validated in value through its role in advancing medicine. The companies meet
the demand of the market seeking novel therapeutics and the medical community's
need for increasing diagnostic capabilities.

Customers

1. Cancer patients

2. Neurodegenerative Disease patients

3. Epileptic Patients

4. Chronic Pain Sufferers

5. Medical Cannabis Patients

6. Medical Practitioners: general health practitioners, neurologists, psychiatrists

7. Physio-therapists

8. Medical Researchers: neuroscientists

9. Hospitals

10. Medical Rehabilitation Facilities

12. Sport Athletes

14. Profession Athlete Trainers

15. Sports Rehabilitation Facilities

Sales/Marketing Strategy

The cutting-edge scientific research will be educated/disclosed through universities

worldwide through medical science conferences which will feature the companies
innovation which is the caveat for the medical community to advance through the
use of advanced novel therapeutics and revolutionary biotech. We rely on leading
and advancing medical science increasing market potential, market capabilities and
retaining the market.

Competitors

Cannabis Producers: lack medical credentials and do not pursue medical scientific
research

There are other companies with portable EEG devices but lack the ability to
translate the brainwave data into usable biometrics for medical purposes

There are a variety of physiotherapy equipment manufactures but none that exist
which harness the power of AI and machine learning to analyze and control
movement intelligently, let alone for brain plasticity

Competitive Advantage

The power behind the acquisition targets/proposed subsidiaries are their role in
leading medical science research and how they advance medicine. All companies
possess proprietary information through their scientific research which adds
significant value to their innovation via the direct role it plays in advancing medicine.
3 Year Forecast

Annual YEAR 1 YEAR 2 YEAR 3

ROYAL SYNTHESIS $1,365,000,000.00 $5,840,000,000.00 $6,989,120,000.00

SALES

ROYAL SYNTHESIS -$699,970,000.00 -$2,975,500,000.00 -$3640018000.00

COSTS

ROYAL SYNTHESIS $665,030,000.00 $2,864,500,000.00 $3349102000.00

REVENUE

AVERTUS SALES $6,000,000.00 $137,000,000.00 $164,000,000.00

AVERTUS COSTS -$1,400,000.00 -$80,730,000.00 -$96,265,000.00

AVERTUS REVENUE $4,600,000.00 $56,270,000.00 $67,735,000.00

NEUROMETRICS JV $69,141,000.00 $83,060,000.00

SALES PROFITS
WITH AVERTUS

NEUROMETRICS -$2770000.00 -$1141000.00 -$1060000.00

COSTS

NEUROMETRICS -$2,770,000.00 $68000000.00 $82000000.00

REVENUE

SYMCOTECH SALES $689,000,000.00 $1,100,000,000.00 $1,230,000,000.00

SYMCOTECH -$251,000,000.00 -$345,000,000.00 -$370,000,000.00

COSTS

SYMCOTECH $438,000,000.00 $755,000,000.00 $860,000,000.00

REVENUE

ANNUALH GH
COSTS

MANAGEMENNT -$2,500,000.00 -$3,000,000.00 -$3,500,000.00

Assistants -$100,000.00 -$120,000.00 -$140,000.00

Office Lease -$500,000.00 -$500,000.00 -$500,000.00

G&A Expenses -$150,000.00 -$150,000.00 -$150,000.00

ONE TIME COST: -$2,000,000.00

Office Construction

TOTAL ANNUAL -$5,250,000.00 -$3,770,000.00 -$4,290,000.00

COSTS HGH
OPERATIONAL
COSTS

REVENUE
STREAMS/LIQUIDITY

ROYAL SYNTHESIS $665,030,000.00 $2,864,500,000.00 $3349102000.00

NET REVENUE

NEUROMETRICS -$2,770,000.00 $68000000.00 $82000000.00

NET REVENUE

AVERTUS NET $4,600,000.00 $56,270,000.00 $67,735,000.00

REVENUE

SYMCOTECH NET $438,000,000.00 $755,000,000.00 $860,000,000.00

REVENUE

TOTAL LIQUIDITY $1,104,860,000.00 $3743770000.00 $4358837000.00

FROM (4) FOUR
SUBSIDIARIES

LIQUIDITY FROM (4) $1,104,860,000.00 $3743770000.00 $4358837000.00

SUBSIDIARIES

HGH ANNUAL -$5,250,000.00 -$3,770,000.00 -$4,290,000.00

COSTS

HGH TOTAL $1,099,610,000.00 $3,740,000,000.00 $4,354,547,000.00

EARNINGS